The global qPCR instruments market size was estimated at USD 1.19 billion in 2025 and is expected to reach USD 2.02 billion by 2033, growing at a CAGR of 7.0% from 2026 to 2033. The rising adoption of molecular diagnostics for infectious disease detection, increasing demand for rapid and high sensitivity testing in clinical and research settings, and the expanding use of qPCR in oncology, genetic testing, and precision medicine are identified as the major growth drivers for this market.
The growth has also been supported by advancements in automated and high throughput qPCR platforms, increased public and private funding for life sciences research, and the continued integration of qPCR technologies into public health surveillance and epidemic preparedness programs worldwide.
The rising prevalence of respiratory viruses such as SARS-CoV-2, influenza, and RSV has kept molecular diagnostics central to healthcare infrastructure planning. For instance, in February 2025, Thermo Fisher Scientific announced U.S. FDA approval for Applied Biosystems TaqPath Flu A, Flu B, COVID-19, RSV Select Panel. This PCR-based multiplex test ensures reliable detection and differentiation of these prevalent viruses. It identifies co-infections, underlining the ongoing importance of qPCR-based assays for monitoring seasonal outbreaks. These products increase the utilization of qPCR platforms in clinical labs. They allow a single instrument to run multiple clinically relevant assays. The result is higher throughput and more efficient use of qPCR instruments across diagnostic workflows. These further drive instrument demand in markets focused on public health and clinical readiness.
The demand for qPCR equipment and consumables was heightened during the SARS-CoV-2 pandemic. The spike in incidence of COVID-19 added significantly to the number of preventive screenings. This was attributed to the fact that the number of COVID-19 patients cannot be ascertained without proper screening, owing to the large number of asymptomatic cases.
Launch of new products is further expected to change certain market dynamics, as it can increase the threat of internal substitution. Furthermore, increasing preference of consumers towards updated and advanced products is creating a demand for technologically advanced products, such as the Mic qPCR system with Bluetooth connectivity and multiple devices that can be connected to the computer simultaneously to run multiple sample sets.
qPCR is extensively used for gene expression analysis, SNP genotyping, copy number variation studies, and validation of next-generation sequencing (NGS) data in genomics research. The growing emphasis on precision medicine and functional genomics has increased the need for accurate nucleic acid quantification, reinforcing qPCR’s role as a standard laboratory tool. This trend is reflected in ongoing product innovation by major industry players. For instance, in July 2025, Bio-Rad Laboratories expanded its PCR technology portfolio with the launch of advanced Droplet Digital PCR platforms, strengthening its molecular analysis offerings for genomics and oncology research. While digital PCR complements qPCR, such developments underscore the broader expansion of molecular quantification technologies driven by genomics research growth.
Prevalence of chronic diseases, infectious diseases, and genetic disorders such as Alzheimer’s, Turner syndrome, & Parkinson’s, has increased rapidly, which is expected to fuel the market. According to CDC, chronic diseases such as cancer, diabetes, kidney diseases, and respiratory diseases including asthma, are accountable for 7 in 10 deaths in the U.S. each year. Faster detection of diseases with PCR can allow for timely & appropriate treatment.
Increasing adoption of qPCR technologies is expected to propel this market. Adoption of qPCR techniques is increasing, owing to their accuracy, automation, precise results, real-time quantification, and sensitivity. qPCR offers a wide range of input nucleic acids, making it an effective and useful technology in research applications.
Government initiatives and public-private partnerships are accelerating the adoption of molecular diagnostics in emerging economies. Investments in national reference laboratories, public health programs, and pandemic preparedness have expanded PCR-based testing beyond urban centers. International funding agencies and global health organizations are supporting the deployment of molecular diagnostic platforms. For instance, in May 2025, Siemens Healthineers invested USD 150 million in the U.S., expanding manufacturing, supply depots, and a 60,000 sq. ft. Experience Center, creating jobs and enhancing healthcare innovation nationwide. These investments further drive qPCR instrument penetration in resource-limited settings.
The growth has also been supported by advancements in automated and high throughput qPCR platforms, increased public and private funding for life sciences research, and the continued integration of qPCR technologies into public health surveillance and epidemic preparedness programs worldwide.
The rising prevalence of respiratory viruses such as SARS-CoV-2, influenza, and RSV has kept molecular diagnostics central to healthcare infrastructure planning. For instance, in February 2025, Thermo Fisher Scientific announced U.S. FDA approval for Applied Biosystems TaqPath Flu A, Flu B, COVID-19, RSV Select Panel. This PCR-based multiplex test ensures reliable detection and differentiation of these prevalent viruses. It identifies co-infections, underlining the ongoing importance of qPCR-based assays for monitoring seasonal outbreaks. These products increase the utilization of qPCR platforms in clinical labs. They allow a single instrument to run multiple clinically relevant assays. The result is higher throughput and more efficient use of qPCR instruments across diagnostic workflows. These further drive instrument demand in markets focused on public health and clinical readiness.
The demand for qPCR equipment and consumables was heightened during the SARS-CoV-2 pandemic. The spike in incidence of COVID-19 added significantly to the number of preventive screenings. This was attributed to the fact that the number of COVID-19 patients cannot be ascertained without proper screening, owing to the large number of asymptomatic cases.
Launch of new products is further expected to change certain market dynamics, as it can increase the threat of internal substitution. Furthermore, increasing preference of consumers towards updated and advanced products is creating a demand for technologically advanced products, such as the Mic qPCR system with Bluetooth connectivity and multiple devices that can be connected to the computer simultaneously to run multiple sample sets.
qPCR is extensively used for gene expression analysis, SNP genotyping, copy number variation studies, and validation of next-generation sequencing (NGS) data in genomics research. The growing emphasis on precision medicine and functional genomics has increased the need for accurate nucleic acid quantification, reinforcing qPCR’s role as a standard laboratory tool. This trend is reflected in ongoing product innovation by major industry players. For instance, in July 2025, Bio-Rad Laboratories expanded its PCR technology portfolio with the launch of advanced Droplet Digital PCR platforms, strengthening its molecular analysis offerings for genomics and oncology research. While digital PCR complements qPCR, such developments underscore the broader expansion of molecular quantification technologies driven by genomics research growth.
Prevalence of chronic diseases, infectious diseases, and genetic disorders such as Alzheimer’s, Turner syndrome, & Parkinson’s, has increased rapidly, which is expected to fuel the market. According to CDC, chronic diseases such as cancer, diabetes, kidney diseases, and respiratory diseases including asthma, are accountable for 7 in 10 deaths in the U.S. each year. Faster detection of diseases with PCR can allow for timely & appropriate treatment.
Increasing adoption of qPCR technologies is expected to propel this market. Adoption of qPCR techniques is increasing, owing to their accuracy, automation, precise results, real-time quantification, and sensitivity. qPCR offers a wide range of input nucleic acids, making it an effective and useful technology in research applications.
Government initiatives and public-private partnerships are accelerating the adoption of molecular diagnostics in emerging economies. Investments in national reference laboratories, public health programs, and pandemic preparedness have expanded PCR-based testing beyond urban centers. International funding agencies and global health organizations are supporting the deployment of molecular diagnostic platforms. For instance, in May 2025, Siemens Healthineers invested USD 150 million in the U.S., expanding manufacturing, supply depots, and a 60,000 sq. ft. Experience Center, creating jobs and enhancing healthcare innovation nationwide. These investments further drive qPCR instrument penetration in resource-limited settings.
Global qPCR Instruments Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global qPCR instruments market report based on instruments, type, and region:Instruments Outlook (Revenue, USD Million, 2021-2033)
- 7500
- QuantStudio
- StepOne/StepOne Plus
- LightCycler
- Cobas 4800/5800/6800/8800
- GeneXpert
- Rotor-Gene Q
- BioFire FilmArray Systems
- BMS Mic System
- Cobas Z480
- CFX
- Others
Type Outlook (Revenue, USD Million, 2021-2033)
- Standalone qPCR Instruments
- Integrated/Automated Molecular Systems
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 qPCR Instruments Market Variables, Trends & Scope
Chapter 4 qPCR Instruments Market: Segment Analysis, by Instruments, 2021-2033 (USD Million)
Chapter 5 qPCR Instruments Market: Segment Analysis, by Type, 2021-2033 (USD Million)
Chapter 6 qPCR Instruments Market: Regional Market Analysis, 2021-2033 (USD Million)
Chapter 7 COMPETITIVE LANDSCAPE
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this qPCR Instruments market report include:- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc
- Danaher Corporation
- Qiagen
- Agilent Technologies, Inc.
- Abbott
- bioMérieux SA
- Quantabio
- Azure Biosystems, Inc.
- Bio Molecular Systems
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 156 |
| Published | February 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.19 Billion |
| Forecasted Market Value ( USD | $ 2.02 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
